CMV Hyperimmunoglobulin Prophylaxis After Heart and Lung Transplantation: One-Year Outcomes from an International, Multicenter, Non-Interventional Study (ISHLT 2026) - Feb 2, 2026 - Abstract #Pub #1477; Pres time: Apr 24, 2026; 04:30 PM - 05:30 PM; Location: Poster Hall; Board #004; "Most patients received concomitant valganciclovir (79%) or ganciclovir (30%), while letermovir (6%) and maribavir (5%) were less common. CMVIG was well tolerated, with no safety concerns. The full study analysis of 500 patients will provide broader insights into CMVIG use across prophylaxis and treatment indications in international transplant practice."
Clinical • Observational data • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
F. Ius 1; P. Jaksch 2; A. Zuckermann 3; A. Bauhofer 4; M. Hauf 4; U. Boeken 5; V. Hettlich 5; P. Ussetti 6; A. Costard-Jaeckle 7; V. Mora 8; V. Monforte 9; B. Skoric 10; C. Tessari 11; K. Santhanakrishnan 12; H. Wilkens 13; L. Godinas 14; F. Dzubur 15; L. Potena 16; U. Schulz 17; C. Grinninger 18; M. Udovičić 19; J. Parmar 20; M. Barten 21
|